Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus

Virology

Volumn 256, Issue 2, 1999, Pages 360-370

  Zhou, Yi Hua ^a   Moriyama, Mitsuhiko ^a   Esumi, Mariko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CHIMPANZEE; CROSS REACTION; EPITOPE MAPPING; HEPATITIS C VIRUS; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS ISOLATION;

ANIMALIA; HEPATITIS C VIRUS; MURINAE; PAN (APE); PAN TROGLODYTES; RNA VIRUSES;

EID: 0033541372     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9635     Document Type: Article

References (30)

1. Ahmed M., Shikata T., Esumi M. Murine humoral immune response against recombinant structural proteins of hepatitis C virus distinct from those of patients. Microbiol. Immunol. 40:1996;169-176.
2. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A. The natural history of community-acquired hepatitis C in the United States. N. Engl. J. Med. 327:1992;1899-1905.
3. Brown D., Powell L., Morris A., Rassam S., Sherlock S., McIntyre N., Zuckerman A. J., Dusheiko G. M. Improved diagnosis of chronic hepatitis C virus infection by detection of antibody to multiple epitopes: Confirmation by antibody to synthetic oligopeptides. J. Med. Virol. 38:1992;167-171.
4. Choo Q.-L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
5. Dyrberg T., Oldstone M. B. Peptides as antigens: Importance of orientation. J. Exp. Med. 164:1986;1344-1349.
6. Esumi M., Ahmed M., Zhou Y.-H., Takahashi H., Shikata T. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus. Virology. 251:1998;158-164.
7. Esumi M., Rikihisa T., Nishimura S., Goto J., Mizuno K., Zhou Y.-H., Shikata T. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch. Virol. 1999.
8. Farci P., Alter H. J., Wong D. C., Miller R. H., Govindarajan S., Engle R., Shapiro M., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA. 91:1994;7792-7796.
9. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H. J., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA. 93:1996;15394-15399.
10. Jackson P., Petril J., Alexander G. J. M., Pearson G., Allain J.-P. Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J. Med. Virol. 51:1997;67-79.
11. Kato N., Ootsuyama Y, Sekiya H., Ohkoshi S., Nakagawa T., Hijikata M., Shimotohno K. Genetic drift in hypervariable region of the viral genome in persistent hepatitis C virus infection. J. Virol. 68:1994;4776-4784.
12. Kato N., Sekiya H., Ootsuyama Y., Nakagawa T., Hijikata M., Ohkoshi S., Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp 70) of hepatitis C virus. J. Virol. 67:1993;3923-3930.
13. Kojima M., Osuga T., Tsuda T., Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selection replication of hepatitis C virus in chimpanzees. Virology. 204:1994;665-672.
14. Kuo G., Choo Q.-L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E., Tegtmeier G. E., Bonino F., Colombo M., Lee W. S., Kuo C., Berger K., Shuster J. R., Overby L. R., Bradly D. W., Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-364.
15. Kurosaki M., Enomoto N., Maruhro F., Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology. 205:1994;161-169.
16. Marchuk D., Drumm M., Saulino A., Collins F. S. Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res. 19:1991.
17. Martell M., Esteban J. I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J. Virol. 66:1992;3225-3229.
18. Okamoto H., Sugiyama Y., Okada S., Kurai. K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y., Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 73:1992;673-679.
19. Puntoriero G., Meola A., Lahm A., Zucchelli S., Ercole B. B., Tafi R., Pezzanera M., Mondelli M. U., Cortese R., Tramontano A., Galfre G., Nicosia A. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 17:1998;3521-3533.
20. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y., Choo Q.-L., Houghton M., Kuo G. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 87:1990;6547-6549.
21. Saitou N., Nei. M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:1987;406-425.
22. Scarselli E., Cerino A., Esposito G., Silini E., Mondelli M. U., Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp 70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J. Virol. 69:1995;4407-4412.
23. Shimizu Y. K., Hijikata M., Iwamoto A., Alter H. J., Purcell R. H., Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68:1994;1494-1500.
24. Shimizu Y. K., Igarashi H., Kiyohara T., Cabezon T., Farci P., Purcell R. H., Yoshikura H. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology. 223:1996;409-412.
25. Taniguchi S., Okamoto H., Sakamoto M., Kojima M., Tsuda F., Tanaka T., Munekata E., Muchmore E. E., Peterson D. A., Mishiro S. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology. 195:1993;297-301.
26. Thompson J. D., Higgins D. G., Gibson T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1994;4673-4680.
27. van Doorn L.-J., Capriles I., Maertens G., DeLeys R., Murray K., Kos T., Schellekens H., Quint W. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J. Virol. 69:1995;773-778.
28. Weiner A. J., Geysen H. M., Christopherson C., Hall J. E., Mason T. J., Saracco G., Bonino F., Crawford K., Marion C. D., Crawford K. A., Brunetto M., Barr P. J., Miyamura T., McHutchinson J., Houghton M. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA. 89:1992;3468-3472.
29. Zibert A., Kraas W., Meisel H., Jung G., Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J. Virol. 71:1997;4123-4127.
30. Zibert A., Schreier E., Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology. 208:1995;653-661.